近距离放疗推量能否改善接受外照射放疗和雄激素剥夺治疗的Gleason分级分组5患者的生存结局?一项系统综述与Meta分析
该系统综述与Meta分析纳入8项回顾性研究,比较Gleason分级分组5患者接受雄激素剥夺治疗联合外照射放疗或外照射放疗+近距离放疗推量的生存结局。外照射放疗+近距离放疗推量在6年(86.8% vs 78.8%,p=0.018)至10年(81.8% vs 66.1%,p<0.001)的远处无转移生存率更高,总风险比为0.53(p=0.02);前列腺癌特异性生存率和总生存率无差异。
要点
- 外照射放疗+近距离放疗推量组6年远处无转移生存率为86.8%,外照射放疗组为78.8%(p=0.018)。
- 外照射放疗+近距离放疗推量组10年远处无转移生存率为81.8%,外照射放疗组为66.1%(p<0.001)。
- 两种治疗方式间前列腺癌特异性生存率和总生存率无差异,毒性差异未评估。
核心结论
- 添加近距离放疗推量与Gleason分级分组5前列腺癌患者长期远处无转移生存改善相关,但其对前列腺癌特异性生存和总生存的影响仍不明确。
- 研究人群间的异质性可能混杂这些结果,并存在偏倚风险担忧,因此需要前瞻性研究进一步阐明近距离放疗推量相关的生存优势,且最终必须权衡该治疗策略的毒性相关影响。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE(PubMed)、EMBASE和Cochrane数据库以识别相关研究。
- 纳入8项回顾性研究,共包括1393例外照射放疗患者和877例外照射放疗+近距离放疗推量患者。
- 提取远处无转移生存、前列腺癌特异性生存和总生存的生存概率并合并,为每种治疗方式创建汇总生存曲线,在固定时间点进行比较。
- 额外分析在直接比较外照射放疗和外照射放疗+近距离放疗推量的研究间使用随机效应模型进行。
主要发现
- 外照射放疗+近距离放疗推量组从6年起远处无转移生存率高于外照射放疗组(86.8% vs 78.8%;p=0.018),并延伸至10年(81.8% vs 66.1%;p<0.001)。
- 总体风险比为0.53(p=0.02)。
- 两种治疗方式间前列腺癌特异性生存率或总生存率无差异。
- 毒性差异未评估。
- 研究间存在广泛的异质性。
局限性
- 纳入的8项研究均为回顾性研究。
- 研究间存在广泛的异质性。
- 研究人群间的异质性可能混杂结果,并存在偏倚风险担忧。
- 毒性差异未评估。
- 作者结论指出需要前瞻性研究进一步阐明近距离放疗推量相关的生存优势,且最终必须权衡该治疗策略的毒性相关影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Localized Gleason Grade Group 5 (GG5) prostate cancer has a poor prognosis and is associated with a higher risk of treatment failure, metastases, and death. Treatment intensification with the addition of a brachytherapy (BT) boost to external beam radiation (EBRT) maximizes local control, which may translate into improved survival outcomes. METHODS: A systematic review and meta-analysis was performed to compare survival outcomes for Gleason GG5 patients treated with androgen deprivation therapy (ADT) and either EBRT or EBRT + BT. The MEDLINE (PubMed), EMBASE and Cochrane databases were searched to identify relevant studies. Survival probabilities for distant metastasis-free survival (DMFS), prostate cancer-specific survival (PCSS), and overall survival (OS) were extracted and pooled to create a summary survival curve for each treatment modality, which were then compared at fixed points in time. An additional analysis was performed among studies directly comparing EBRT and EBRT + BT using a random-effects model. RESULTS: Eight retrospective studies were selected for inclusion, representing a total of 1393 EBRT patients and 877 EBRT + BT patients. EBRT + BT was associated with higher DMFS starting at 6 years (86.8 % vs 78.8 %; p = 0.018) and extending out to 10 years (81.8 % vs 66.1 %; p < 0.001), with an overall hazard ratio of 0.53 (p = 0.02). There was no difference in PCSS or OS between treatment modalities. Differences in toxicity were not assessed. There was a wide range of heterogeneity between studies. CONCLUSION: The addition of BT boost is associated with improved long-term DMFS in Gleason GG5 prostate cancer, but its impact on PCSS and OS remains unclear. These results may be confounded by the heterogeneity across study populations with concern for a risk of bias. Therefore, prospective studies are necessary to further elucidate the survival advantage associated with BT boost, which must ultimately be weighed against the toxicity-related implications of this treatment strategy.
引用
- Tang T, Gulstene S, McArthur E, et al. Does brachytherapy boost improve survival outcomes in Gleason Grade Group 5 patients treated with external beam radiotherapy and androgen deprivation therapy? A systematic review and meta-analysis. Clin Transl Radiat Oncol. 2022. PMID: 36353652. doi:10.1016/j.ctro.2022.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。